- Home
- SILC vs BCAB Comparison
SILC vs BCAB Comparison
Compare SILC & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SILC | BCAB |
|---|---|---|
| Founded | 1987 | 2007 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 110.7M | 12.5M |
| IPO Year | 2002 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SILC | BCAB |
|---|---|---|
| Price | $19.05 | $0.17 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 3 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 38.1K | ★ 1.6M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 44.19 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $300,000.00 |
| Revenue This Year | $17.17 | N/A |
| Revenue Next Year | $12.28 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.44 | $0.13 |
| 52 Week High | $23.00 | $1.43 |
Technical Indicators
Market Signals| Indicator | SILC | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 47.54 | 38.09 |
| Support Level | $18.55 | $0.14 |
| Resistance Level | $21.12 | $0.27 |
| Average True Range (ATR) | 1.21 | 0.02 |
| MACD | -0.24 | 0.01 |
| Stochastic Oscillator | 8.81 | 11.00 |
Price Performance
Historical ComparisonAbout SILC Silicom Ltd
Silicom Ltd designs and manufactures networking and data infrastructure solutions for various servers, server-based systems, and communications devices. Its product categories consist of Server Adapters, Edge Networking Solutions, FPGA-Based Cards, x86 Open Appliances, Bypass Switches, and TAPs. Geographically, it derives a majority of its revenue from North America and also has a presence in Europe and Asia-Pacific.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.